35 Result(s)
within
François Bertucci
Cancer Research
-
Article
Open AccessManagement and outcomes of adolescent and young adult sarcoma patients: results from the French nationwide database NETSARC
The initial management of patients with sarcoma is a critical issue. We used the nationwide French National Cancer Institute-funded prospective sarcoma database NETSARC to report the management and oncologic outc...
-
Article
Open AccessComparative transcriptional analyses of preclinical models and patient samples reveal MYC and RELA driven expression patterns that define the molecular landscape of IBC
Inflammatory breast cancer (IBC) is an aggressive disease for which the spectrum of preclinical models was rather limited in the past. More recently, novel cell lines and xenografts have been developed. This s...
-
Article
Open AccessDeterminants of the access to remote specialised services provided by national sarcoma reference centres
Spatial inequalities in cancer management have been evidenced by studies reporting lower quality of care or/and lower survival for patients living in remote or socially deprived areas. NETSARC+ is a national r...
-
Article
Open AccessProspective high-throughput genome profiling of advanced cancers: results of the PERMED-01 clinical trial
The benefit of precision medicine based on relatively limited gene sets and often-archived samples remains unproven. PERMED-01 (NCT02342158) was a prospective monocentric clinical trial assessing, in adults wi...
-
Article
Open AccessThe CINSARC signature predicts the clinical outcome in patients with Luminal B breast cancer
CINSARC, a multigene expression signature originally developed in sarcomas, was shown to have prognostic impact in various cancers. We tested the prognostic value for disease-free survival (DFS) of CINSARC in ...
-
Article
Open AccessQuantitative hormone receptor (HR) expression and gene expression analysis in HR+ inflammatory breast cancer (IBC) vs non-IBC
The purpose of this study was to determine the prognostic role of hormone receptor (HR) on inflammatory breast cancer (IBC) to elucidate its aggressive biological behavior.
-
Article
Open AccessThe therapeutic response of ER+/HER2− breast cancers differs according to the molecular Basal or Luminal subtype
The genomics-based molecular classifications aim at identifying more homogeneous classes than immunohistochemistry, associated with a more uniform clinical outcome. We conducted an in silico analysis on a meta...
-
Article
Open AccessECT2 associated to PRICKLE1 are poor-prognosis markers in triple-negative breast cancer
Triple-negative breast cancers (TNBC) are poor-prognosis tumours candidate to chemotherapy as only systemic treatment. We previously found that PRICKLE1, a prometastatic protein involved in planar cell polarit...
-
Article
Open AccessESR1 mutations in metastatic lobular breast cancer patients
Invasive lobular breast cancer (ILC) represents the second most common histology of breast cancer after invasive ductal breast cancer (IDC), accounts for up to 15% of all invasive cases and generally express t...
-
Article
Open AccessThe immunologic constant of rejection classification refines the prognostic value of conventional prognostic signatures in breast cancer
The immunologic constant of rejection (ICR) is a broad phenomenon of Th-1 immunity-mediated, tissue-specific destruction.
-
Article
Open AccessPrognostic and predictive factors for angiosarcoma patients receiving paclitaxel once weekly plus or minus bevacizumab: an ancillary study derived from a randomized clinical trial
We report here a correlation analysis conducted along with a phase II trial assessing bevacizumab in combination with weekly paclitaxel.
-
Article
Open AccessReversible rituximab-induced rectal Kaposi’s sarcoma misdiagnosed as ulcerative colitis in a patient with HIV-negative follicular lymphoma
Kaposi’s sarcoma is a low-grade mesenchymal angioproliferative tumor, most commonly observed in immunocompromised individuals, such as HIV-infected patients. Iatrogenic Kaposi’s sarcoma occurs in patients unde...
-
Article
Open AccessValidation and comparison of the molecular classifications of pancreatic carcinomas
Four molecular classifications of pancreatic ductal adenocarcinoma (PDAC), biologically and clinically relevant and based on gene expression profiles, were established in the recent years, including the Collis...
-
Article
Open AccessErratum to: HDAC6 activity is a non-oncogene addiction hub for inflammatory breast cancers
-
Article
Open AccessHDAC6 activity is a non-oncogene addiction hub for inflammatory breast cancers
Inflammatory breast cancer (IBC) is the most lethal form of breast cancers with a 5-year survival rate of only 40 %. Despite its lethality, IBC remains poorly understood which has greatly limited its therapeut...
-
Article
Open AccessHigh-grade soft tissue sarcoma arising in a desmoid tumor: case report and review of the literature
Desmoid tumors are rare benign monoclonal fibroblastic tumors. Their aggressiveness is local with no potential for metastasis or dedifferentiation. Here we report on a 61-year-old patient who presented a local...
-
Article
Open AccessThe E2F4 prognostic signature is also predictive of the pathological response of breast cancer to chemotherapy
-
Article
Open AccessThe off-label use of targeted therapies in sarcomas: the OUTC’S program
Few targeted therapies (TTs) are registered for sarcoma treatment despite numerous phase II studies and yet there are potential treatment options for patients after standard treatment escape. The French Sarcom...
-
Article
Open AccessClaudin-low breast cancers: clinical, pathological, molecular and prognostic characterization
The lastly identified claudin-low (CL) subtype of breast cancer (BC) remains poorly described as compared to the other molecular subtypes. We provide a comprehensive characterization of the largest series of C...
-
Article
Open AccessComparison of molecular subtype distribution in triple-negative inflammatory and non-inflammatory breast cancers
Because of its high rate of metastasis, inflammatory breast cancer (IBC) has a poor prognosis compared with non-inflammatory types of breast cancer (non-IBC). In a recent study, Lehmann and colleagues identifi...
